Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?

Pancreatic cancer is extremely resistant to chemo- and radiation-therapies due to its inherent genetic instability, the local immunosuppressive microenvironment and the remarkable desmoplastic stromal changes which characterize this cancer. Therefore, there is an urgent need for improvement on stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunet, Laura Rosa, Hagemann, Thorsten, Gaya, Andrew, Mudan, Satvinder, Marabelle, Aurelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839322/
https://www.ncbi.nlm.nih.gov/pubmed/27141395
http://dx.doi.org/10.1080/2162402X.2015.1112942
_version_ 1782428125082157056
author Brunet, Laura Rosa
Hagemann, Thorsten
Gaya, Andrew
Mudan, Satvinder
Marabelle, Aurelien
author_facet Brunet, Laura Rosa
Hagemann, Thorsten
Gaya, Andrew
Mudan, Satvinder
Marabelle, Aurelien
author_sort Brunet, Laura Rosa
collection PubMed
description Pancreatic cancer is extremely resistant to chemo- and radiation-therapies due to its inherent genetic instability, the local immunosuppressive microenvironment and the remarkable desmoplastic stromal changes which characterize this cancer. Therefore, there is an urgent need for improvement on standard current therapeutic options. Immunotherapies aimed at harnessing endogenous antitumor immunity have shown promise in multiple tumor types. In this review, we give an overview of new immune-related therapeutic strategies currently being tested in clinical trials in pancreatic cancer. We propose that immunotherapeutic strategies in combination with current therapies may offer new hopes in this most deadly disease.
format Online
Article
Text
id pubmed-4839322
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48393222016-05-02 Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Brunet, Laura Rosa Hagemann, Thorsten Gaya, Andrew Mudan, Satvinder Marabelle, Aurelien Oncoimmunology Review Pancreatic cancer is extremely resistant to chemo- and radiation-therapies due to its inherent genetic instability, the local immunosuppressive microenvironment and the remarkable desmoplastic stromal changes which characterize this cancer. Therefore, there is an urgent need for improvement on standard current therapeutic options. Immunotherapies aimed at harnessing endogenous antitumor immunity have shown promise in multiple tumor types. In this review, we give an overview of new immune-related therapeutic strategies currently being tested in clinical trials in pancreatic cancer. We propose that immunotherapeutic strategies in combination with current therapies may offer new hopes in this most deadly disease. Taylor & Francis 2015-12-18 /pmc/articles/PMC4839322/ /pubmed/27141395 http://dx.doi.org/10.1080/2162402X.2015.1112942 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Review
Brunet, Laura Rosa
Hagemann, Thorsten
Gaya, Andrew
Mudan, Satvinder
Marabelle, Aurelien
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
title Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
title_full Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
title_fullStr Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
title_full_unstemmed Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
title_short Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
title_sort have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839322/
https://www.ncbi.nlm.nih.gov/pubmed/27141395
http://dx.doi.org/10.1080/2162402X.2015.1112942
work_keys_str_mv AT brunetlaurarosa havelessonsfrompastfailuresbroughtusclosertothesuccessofimmunotherapyinmetastaticpancreaticcancer
AT hagemannthorsten havelessonsfrompastfailuresbroughtusclosertothesuccessofimmunotherapyinmetastaticpancreaticcancer
AT gayaandrew havelessonsfrompastfailuresbroughtusclosertothesuccessofimmunotherapyinmetastaticpancreaticcancer
AT mudansatvinder havelessonsfrompastfailuresbroughtusclosertothesuccessofimmunotherapyinmetastaticpancreaticcancer
AT marabelleaurelien havelessonsfrompastfailuresbroughtusclosertothesuccessofimmunotherapyinmetastaticpancreaticcancer

Ejemplares similares